Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG1837 in Healthy Subjects
NCT02325037Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG1837 in cystic fibrosis (CF) (4 arms), sponsored by Galapagos NV. Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory parameters and 3 more. Started Dec 2014; status: completed.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02325037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325037.